No abstract available.
Peptic Ulcer*

No abstract available.
Anal Canal* ; Carcinoma, Squamous Cell*

No abstract available.
Magnetic Resonance Imaging* ; Osteosarcoma*

No abstract available.
Child* ; Humans ; Incidence* ; Leukemia*

No abstract available.
Hemangioma, Cavernous*

PURPOSE: Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) exhibits variable lower urinary tract symptoms (LUTS). The aim of this study was to evaluate the incidence of LUTS and the efficacy of an anticholinergic agent in young and middle-aged CP/CPPS patients. METHODS: Ninety-six men with CP/CPPS were randomly assigned in a single-blind fashion and received either ciprofloxacin (group 1, 49 patients) or ciprofloxacin and solifenacin (5 mg/day; group 2, 47 patients) for 8 weeks. The National Institutes of Health chronic prostatitis symptom index (NIH-CPSI), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function-5 (IIEF-5) were used to grade the patients' symptoms and the quality of life impact at the start of the study, and at 4 and 8 weeks from the initiation of the study. RESULTS: There was no significant difference between groups 1 and 2 with respect to age, duration of disease, or sub-domains of the IPSS, NIH-CPSI, or IIEF-5 at baseline. Of these patients, 67.4% had LUTS. Statistically significant differences were determined via the NIH-CPSI for total score and the pain and urinary domain scores. Statistically significant differences were determined via the IPSS for total score and the storage domain score. The total score of the IIEF-5 increased, but the change was not significant. There was no statistically significant difference in residual urine. CONCLUSIONS: Many CP/CPPS patients had LUTS. Solifenacin in CP/CPPS demonstrated improvements in the NIH-CPSI and the IPSS total score and storage score. Storage factors significantly improved via the NIH-CPSI and IPSS assessments in the solifenacin treatment group.
Cholinergic Antagonists ; Ciprofloxacin ; Humans ; Incidence ; Lower Urinary Tract Symptoms ; Male ; National Institutes of Health (U.S.) ; Pelvic Pain ; Prospective Studies ; Prostate ; Prostatitis ; Quality of Life ; Quinuclidines ; Solifenacin Succinate ; Tetrahydroisoquinolines

No abstract available.

BACKGROUND: Immunologic marker studies and cytogenetic studies as well as morphological studies are frequently performed for the differential diagnosis of acute leukemia. We investigated the relationship of between immunophenotyping and cytogenetic abnormalities in acute myelogenous leukemias (AMLs). METHODS: Total 153 cases of AMLs were included. Morphological, cytochemical, immunophenotypic, and cytogenetic studies were performed. We classified the AML cases according to immunophenotyping and investigated the association between cytogenetic results and immunophenotype. And we compared differences between the AML group with lymphoid markers and that without them. RESULTS: In 153 cases of AMLs, lymphoid markers (CD2, CD5, CD7, CD19, CD10) were coexpressed in 59 cases (38.6%). Cytogenetic abnormalities were in 106 cases (69.3%). No significant difference in cytogenetic abnormalities was observed between the group with lymphoid markers and without them (76.3% vs. 64.9%, P>0.05). t(8;21)(q22;22) was significantly more frequent in CD19+AMLs (78.3% vs. 7.7%, P<0.0001), compared to CD19-AMLs. In CD2+AMLs, t(15;17)(q24;q21) was significantly more frequent than in CD2-AMLs (81.8% vs. 8.5%, P<0.0001). CD7+AML cases showed fewer cytogenetic abnormalities than AML with other lymphoid markers and various chromosomal abnormalities. CONCLUSIONS: In AML, cytogenetic abnormalities were different in relation to aberrant lymphoid markers. CD19 vs. t(8;21) and CD2 vs. t(15;17) were closely associated with each other. It is thought that CD7+AML cases are heterogeneous group. We need the study for response to therapy and prognosis in AMLs with lymphoid markers so that the data of this study can be helpful for the diagnosis and treatment.
Biomarkers ; Chromosome Aberrations* ; Cytogenetics* ; Diagnosis ; Diagnosis, Differential ; Humans ; Immunophenotyping ; Leukemia ; Leukemia, Myeloid, Acute* ; Prognosis

Primary CNS lymphoma (PCNSL) is a very uncommon disease in children, and usually treated by chemotherapy, combined with focal or craniospinal radiotherapy (RT). However, adverse effects of RT are a concern. We evaluated the outcomes of childhood PCNSL, treated with systemic and intrathecal chemotherapy, but without RT. For fifteen years, six patients among 175 of non-Hodgkin lymphoma were diagnosed as PCNSL in Seoul National University Children's Hospital and we analyzed their medical records retrospectively. Their male:female ratio was 5:1, and median age was 10.1 yr. The primary sites were the sellar area in three patients, parietal area in one, cerebellum in one, and multiple areas in one. Their pathologic diagnoses were diffuse large B-cell lymphoma in three patients, Burkitt lymphoma in two, and undifferentiated B-cell lymphoma in one. Five were treated with the LMB96 treatment protocol, and one was treated with the CCG-106B protocol. None had RT as a first-line treatment. One patient had a local relapse and received RT and salvage chemotherapy, without success. No patient had treatment-related mortality. Their estimated 5-yr event-free and overall survival rates were both 83.3%. In conclusion, PCNSL is a rare disease in childhood, but successfully treated by chemotherapy without RT.
Adolescent ; Antineoplastic Combined Chemotherapy Protocols/*therapeutic use ; Central Nervous System Neoplasms/diagnosis/*drug therapy ; Child ; Child, Preschool ; Cyclophosphamide/therapeutic use ; Cytarabine/therapeutic use ; Disease-Free Survival ; Doxorubicin/therapeutic use ; Etoposide/therapeutic use ; Female ; Humans ; Hydrocortisone/therapeutic use ; Infant ; Leucovorin/therapeutic use ; Lymphoma, Non-Hodgkin/diagnosis/*drug therapy ; Male ; Methotrexate/therapeutic use ; Prednisone/therapeutic use ; Recurrence ; Retrospective Studies ; Tomography, X-Ray Computed ; Treatment Outcome ; Vincristine/therapeutic use

Hereditary spherocytosis (HS) is a common inherited erythrocyte membrane disorder characterized by chronic hemolytic anemia. Clinical manifestations and biochemical abnormalities of HS are heterogeneous. In this study, we investigated erythrocyte membrane protein defects in 27 Korean HS cases. Utilizing both the Fairbanks system and the Laemmli system, sodium dodecyl sulfate polyacrylamide gel electrophoresis of erythrocyte membrane proteins was performed. Proteins were stained with Coomassie brilliant blue and gels were scanned using a densitometer. We detected spectrin deficiency in 7.4% of cases (2/27), ankyrin deficiency in 29.6% (8/27), combined spectrin and ankyrin deficiency in 3.7% (1/27), band 3 deficiency in 11.1% (3/27) and protein 4.2 deficiency in 14.8% (4/27). Membrane protein deficiencies were not observed in nine cases (33.3%, 9/27). Members of two of seven families tested showed the same protein defects as the proband. Ankyrin deficiency alone and combined with spectrin deficiency accounted for 33.3% of cases (9/27), and they were the most common biochemical defects in Korean HS cases. Protein 4.2 deficiency caused HS more frequently in Koreans than in Caucasians.
Ankyrins/analysis* ; Band 3 Protein/analysis* ; Erythrocyte Membrane/chemistry* ; Human ; Korea ; Spectrin/analysis* ; Spherocytosis, Hereditary/blood*